211 related articles for article (PubMed ID: 31885183)
1. Identification of RNPC3 as a novel JAK2 fusion partner gene in B-acute lymphoblastic leukemia refractory to combination therapy including ruxolitinib.
Chen X; Wang F; Zhang Y; Ma X; Liu M; Cao P; Zhou L; Wang L; Zhang X; Wang T; Liu H
Mol Genet Genomic Med; 2020 Mar; 8(3):e1110. PubMed ID: 31885183
[TBL] [Abstract][Full Text] [Related]
2. Novel JAK2 rearrangement resulting from a t(9;22)(p24;q11.2) in B-acute lymphoblastic leukemia.
Tirado CA; Chen W; Huang LJ; Laborde C; Hiemenz MC; Valdez F; Ho K; Winick N; Lou Z; Koduru P
Leuk Res; 2010 Dec; 34(12):1674-6. PubMed ID: 20594592
[TBL] [Abstract][Full Text] [Related]
3. Ruxolitinib/nilotinib cotreatment inhibits leukemia-propagating cells in Philadelphia chromosome-positive ALL.
Kong Y; Wu YL; Song Y; Shi MM; Cao XN; Zhao HY; Qin YZ; Lai YY; Jiang H; Jiang Q; Huang XJ
J Transl Med; 2017 Aug; 15(1):184. PubMed ID: 28854975
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic characteristics, genetic features, and treatment options for acute lymphoblastic leukemia with JAK2 rearrangement-A 10-case study and literature review.
Zhang L; Shah B; Zhang Y; Tashkandi H; Xiao W; Fernandez-Pol S; Vergara-Lluri M; Hussaini M; Song J; Lancet J; Moscinski L; Yun S; Lu CM; Medeiros LJ; Tang G
Hum Pathol; 2023 Jun; 136():1-15. PubMed ID: 36958463
[TBL] [Abstract][Full Text] [Related]
5. The diagnostic challenges and clinical course of a myeloid/lymphoid neoplasm with eosinophilia and
Lee WY; Pfau RB; Choi SM; Yang J; Xiao H; Putnam EM; Ryan RJ; Bixby DL; Shao L
Cold Spring Harb Mol Case Stud; 2020 Apr; 6(2):. PubMed ID: 32238402
[TBL] [Abstract][Full Text] [Related]
6. Novel SSBP2-JAK2 fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre-B acute lymphocytic leukemia.
Poitras JL; Dal Cin P; Aster JC; Deangelo DJ; Morton CC
Genes Chromosomes Cancer; 2008 Oct; 47(10):884-9. PubMed ID: 18618714
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with
Ding YY; Stern JW; Jubelirer TF; Wertheim GB; Lin F; Chang F; Gu Z; Mullighan CG; Li Y; Harvey RC; Chen IM; Willman CL; Hunger SP; Li MM; Tasian SK
Haematologica; 2018 Sep; 103(9):e427-e431. PubMed ID: 29773603
[No Abstract] [Full Text] [Related]
8. Integration of ruxolitinib into dose-intensified therapy targeted against a novel JAK2 F694L mutation in B-precursor acute lymphoblastic leukemia.
Mayfield JR; Czuchlewski DR; Gale JM; Matlawska-Wasowska K; Vasef MA; Nickl C; Pickett G; Ness SA; Winter SS
Pediatr Blood Cancer; 2017 May; 64(5):. PubMed ID: 27860260
[TBL] [Abstract][Full Text] [Related]
9. Sustained remission after ruxolitinib and chimeric antigen receptor T-cell therapy bridged to a second allogeneic hematopoietic stem cell transplantation for relapsed Philadelphia chromosome-like B-cell precursor acute lymphoblastic leukemia with novel NPHP3-JAK2 fusion.
Chen X; Yuan L; Zhou J; Wang F; Zhang Y; Ma X; Cao P; Fang J; Chen J; Zhou X; Wu Q; Liu M; Liu H
Genes Chromosomes Cancer; 2022 Jan; 61(1):55-58. PubMed ID: 34418218
[No Abstract] [Full Text] [Related]
10. IGF2BP1: a novel IGH translocation partner in B acute lymphoblastic leukemia.
Gu G; Sederberg MC; Drachenberg MR; South ST
Cancer Genet; 2014; 207(7-8):332-4. PubMed ID: 25195122
[TBL] [Abstract][Full Text] [Related]
11. Transforming and tumorigenic activity of JAK2 by fusion to BCR: molecular mechanisms of action of a novel BCR-JAK2 tyrosine-kinase.
Cuesta-Domínguez Á; Ortega M; Ormazábal C; Santos-Roncero M; Galán-Díez M; Steegmann JL; Figuera Á; Arranz E; Vizmanos JL; Bueren JA; Río P; Fernández-Ruiz E
PLoS One; 2012; 7(2):e32451. PubMed ID: 22384256
[TBL] [Abstract][Full Text] [Related]
12. Occurrence of TEL-AML1 fusion resulting from (12;21) translocation in human early B-lineage leukemia cell lines.
Uphoff CC; MacLeod RA; Denkmann SA; Golub TR; Borkhardt A; Janssen JW; Drexler HG
Leukemia; 1997 Mar; 11(3):441-7. PubMed ID: 9067587
[TBL] [Abstract][Full Text] [Related]
13. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia.
Spinelli O; Peruta B; Tosi M; Guerini V; Salvi A; Zanotti MC; Oldani E; Grassi A; Intermesoli T; Micò C; Rossi G; Fabris P; Lambertenghi-Deliliers G; Angelucci E; Barbui T; Bassan R; Rambaldi A
Haematologica; 2007 May; 92(5):612-8. PubMed ID: 17488684
[TBL] [Abstract][Full Text] [Related]
14. BCR-JAK2 fusion in a myeloproliferative neoplasm with associated eosinophilia.
He R; Greipp PT; Rangan A; Mai M; Chen D; Reichard KK; Nelsen LL; Pardanani A; Hanson CA; Viswanatha DS
Cancer Genet; 2016 May; 209(5):223-8. PubMed ID: 27134074
[TBL] [Abstract][Full Text] [Related]
15. JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias.
Kim SK; Knight DA; Jones LR; Vervoort S; Ng AP; Seymour JF; Bradner JE; Waibel M; Kats L; Johnstone RW
Genes Dev; 2018 Jun; 32(11-12):849-864. PubMed ID: 29907650
[TBL] [Abstract][Full Text] [Related]
16. Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study.
Tang G; Sydney Sir Philip JK; Weinberg O; Tam W; Sadigh S; Lake JI; Margolskee EM; Rogers HJ; Miranda RN; Bueso-Ramos C C; Hsi ED; Orazi A; Hasserjian RP; Arber DA; Bagg A; Wang SA
Mod Pathol; 2019 Apr; 32(4):490-498. PubMed ID: 30401948
[TBL] [Abstract][Full Text] [Related]
17. Identification of
Zhang XY; Dai HP; Li Z; Yin J; Lang XP; Yang CX; Xiao S; Zhu MQ; Liu DD; Liu H; Shen HJ; Wu DP; Tang XW
Front Oncol; 2020; 10():611467. PubMed ID: 33505919
[TBL] [Abstract][Full Text] [Related]
18. Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V>F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms.
Najfeld V; Cozza A; Berkofsy-Fessler W; Prchal J; Scalise A
Exp Hematol; 2007 Nov; 35(11):1668-76. PubMed ID: 17976519
[TBL] [Abstract][Full Text] [Related]
19. Hematopoietic stem cell transplantation for pediatric mature B-cell acute lymphoblastic leukemia with non-L3 morphology and MLL-AF9 gene fusion: three case reports and review of the literature.
Sarashina T; Iwabuchi H; Miyagawa N; Sekimizu M; Yokosuka T; Fukuda K; Hamanoue S; Iwasaki F; Goto S; Shiomi M; Imai C; Goto H
Int J Hematol; 2016 Jul; 104(1):139-43. PubMed ID: 27084248
[TBL] [Abstract][Full Text] [Related]
20. Identification of SPAG9 as a novel JAK2 fusion partner gene in pediatric acute lymphoblastic leukemia with t(9;17)(p24;q21).
Kawamura M; Taki T; Kaku H; Ohki K; Hayashi Y
Genes Chromosomes Cancer; 2015 Jul; 54(7):401-8. PubMed ID: 25951811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
